Population pharmacokinetic study of memantine: Effects of clinical and genetic factors

Clinical Pharmacokinetics

Volumn 52, Issue 3, 2013, Pages 211-223

  Noetzli, Muriel ^a   Guidi, Monia ^b,f   Ebbing, Karsten ^b   Eyer, Stephan ^b   Wilhelm, Laurence ^c   Michon, Agnès ^d   Thomazic, Valérie ^d   Alnawaqil, Abdel Messieh ^e   Maurer, Sophie ^a   Zumbach, Serge ^e   Giannakopoulos, Panteleimon ^d   Von Gunten, Armin ^b   Csajka, Chantal ^b,f   Eap, Chin B ^a,f  

^a Hopital de Cery   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c University Hospital Geneva ^*  (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^e Hopital Cantonal de Fribourg   (Switzerland)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CATION TRANSPORT PROTEIN; CELL NUCLEUS RECEPTOR; MEMANTINE; MULTIDRUG RESISTANCE PROTEIN 1; NR1I2 PROTEIN; NR1I3 PROTEIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; SLC22A5 PROTEIN; SLC47A1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONSTIPATION; CROSS-SECTIONAL STUDY; DEMENTIA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMNOLENCE; STEADY STATE;

AGED; AGED, 80 AND OVER; CARRIER PROTEINS; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; MALE; MEMANTINE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84877057459     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0032-2     Document Type: Article

References (49)

1. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother. 2011;12(5):787-800.
2. EMEA. EPAR (European public assessment report): Axura. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000378/WC500029678.pdf. Accessed 20 Dec 2011.
3. EMEA. Memantine scientific discussion. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Scientific-Discussion/human/000378/WC500029674.pdf. Accessed 20 Dec 2011.
4. Freudenthaler S, Görtelmeyer R, Pantev M, et al. Dose-response analysis to support dosage recommendations for memantine [abstract]. Naunyn Schmiedeberg's Arch Pharmacol. 1996;353:R606.
5. Yee SW, Chen L, Giacomini KM. Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010;11(4):475-9.
6. Busch AE, Karbach U, Miska D, et al. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998;54(2):342-52.
7. Ciarimboli G. Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol. 2011;7(2):159-74.
8. Kang HJ, Song IS, Shin HJ, et al. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab Dispos. 2007;35(4):667-75.
9. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12(5):395-405.
10. Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetics variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12:591-5.
11. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61.
12. Ha Choi J, Wah Yee S, Kim MJ, et al. Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics. 2009;19(10):770-80.
13. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81-98.
14. Zolk O. Current understanding of the pharmacogenomics of metformin. Clin Pharmacol Ther. 2009;86(6):595-8.
15. Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab. 2005;6(4):309-28.
16. Le Vee M, Lecureur V, Moreau A, et al. Differential regulation of drug transporter expression by hepatocyte growth factor in primary human hepatocytes. Drug Metab Dispos. 2009;37(11):2228-35.
17. Maeda T, Oyabu M, Yotsumoto T, et al. Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos. 2007;35(9):1580-6.
18. D'Argenio G, Petillo O, Margarucci S, et al. Colon OCTN2 gene expression is up-regulated by peroxisome proliferator-activated receptor gamma in humans and mice and contributes to local and systemic carnitine homeostasis. J Biol Chem. 2010;285(35):27078-87.
19. Cho SK, Yoon JS, Lee MG, et al. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther. 2011;89(3):416-21.
20. Lamba V, Panetta JC, Strom S, et al. Genetic predictors of interindividual variability in hepatic CYP3A4 expression. J Pharmacol Exp Ther. 2010;332(3):1088-99.
21. Klein K, Winter S, Turpeinen M, et al. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol. 2010;1:1-20.
22. Noetzli M, Choong E, Ansermot N, et al. Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring. Ther Drug Monit. 2011;33(2):227-38.
23. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86(3):299-306.
24. Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52(2):117-22.
25. More SS, Li S, Yee SW, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010;9(4):1058-69.
26. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422-31.
27. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20(4):217-30.
28. Urban TJ, Gallagher RC, Brown C, et al. Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol. 2006;70(5):1602-11.
29. Crettol S, Déglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80(6):668-81.
30. Beal SL, Sheiner LB, Boeckmann A, et al. NONMEM user's guides (1989-2009). Ellicot City: Icon Development Solutions; 2009.
31. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-57.
32. Stevens LA, Manzi J, Levey AS, et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis. 2007;50(1):21-35.
33. Arab-Alameddine M, Di Lulio J, Buclin T, et al. Pharmacogenetic-based population Pharmacokinetic analysis of efavirenz in HIV-1 infected individuals. Clin Pharmacol Ther. 2009;85(5):485-94.
34. FDA. Drug development and drug interactions. http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm080499.htm. Accessed 21 Sep 2012.
35. PharmGkb. Agonists/ligands of hPXR. http://www.pharmgkb.org/gene/PA378? tabType=tabVip. Accessed 20 Dec 2011.
36. National Center for Biotechnology Information - dbSNP. http://www.ncbi.nlm.nih.gov/snp. Accessed 20 Dec 2011.
37. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195-235.
38. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46(7):599-612.
39. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79(1):134-43.
40. Meetam P, Srimaroeng C, Soodvilai S, et al. Regulatory role of testosterone in organic cation transport: in vivo and in vitro studies. Biol Pharm Bull. 2009;32(6):982-7.
41. Slitt AL, Cherrington NJ, Hartley DP, et al. Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab Dispos. 2002;30(2):212-9.
42. Rao N, Chou T, Ventura D, et al. Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. Clin Ther. 2005;27(10):1596-606.
43. Freudenthaler S, Meineke I, Schreeb KH, et al. Influence of urine pH and urinary flow on the renal excretion of memantine. Br J Clin Pharmacol. 1998;46(6):541-6.
44. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234(1):4-33.
45. Fanta S, Jonsson S, Karlsson MO, et al. Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism. J Clin Pharmacol. 2010;50(5):581-97.
46. Op den Buijsch RAM, Cheung CY, De Vries JE, et al. Pregnane X receptor (PXR) polymorphisms involved in the tacrolimus pharmacokinetics. Ther Drug Monit. 2007;29(4):484.
47. Siccardi M, D'Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis. 2008;47:1222-5.
48. Oleson L, von Moltke LL, Greenblatt DJ, et al. Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica. 2010;40(2):146-62.
49. Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos. 2008;36(1):169-81.